


**Product Name** : Senexin B  
**Cat. No.** : PC-42425  
**CAS No.** : 1449228-40-3  
**Molecular Formula** : C<sub>27</sub>H<sub>26</sub>N<sub>6</sub>O  
**Molecular Weight** : 450.53  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



### Biological Activity

Senexin B (SNX2-1-165) is a highly potent, selective and orally available **CDK8/CDK19** inhibitor with IC<sub>50</sub> of 24-50 nM. Senexin B (SNX2-1-165) exhibits selectivity for CDK8 and CDK19 with K<sub>d</sub> of 140 nM and 80 nM, respectively. Senexin B (SNX2-1-165) significantly suppresses tumor growth in ER-positive breast cancer xenografts.

### References

Donald C. Porter, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19.

Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. Publication number: WO2013116786 A1.

McDermott MS, et al. **Oncotarget**. 2017 Feb 21;8(8):12558-12575.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com